SecBot SecBot
8-K ·Filed Sep 14, 2026

NRXP

NRX Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed2mo ago SEC0001437749-26-030228
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

This is a routine investor presentation filing with no new material information. Monitor for future filings containing clinical updates, financial results, or financing activities for trading catalysts.

DirectionNeutral
Confidencelow
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.49
T+0 close · Sep 14, 2026 · via day close
Latest settled
−18.34%
T+20 · $2.85 · next T+60 in 21d
Vs SPY
−20.60%
α at T+20
Latest observation
−28.66%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $3.49entry
  2. T+1 · 2mo ago −2.58%α −2.12% · $3.40
  3. T+5 · 8w ago −5.73%α −5.84% · $3.29
  4. T+20 · 5w ago −18.34%α −20.60% · $2.85
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors and analysts on September 8, 2026. The filing is a routine Regulation FD disclosure with no new material financial data, guidance, or corporate events. The presentation content was not extractable from the provided documents, limiting analysis to the filing's procedural nature.

Key Facts

  • NRX Pharmaceuticals filed an 8-K on September 14, 2026, regarding Item 7.01 Regulation FD Disclosure.
  • The filing furnishes an investor presentation (Exhibit 99.1) used in meetings on September 8, 2026.
  • No financial results, guidance, or material corporate events were disclosed in the 8-K body.
  • The investor presentation content was not available for analysis.

Financial Impact

Not specified

Risk Factors

  • No material financial or operational data disclosed; stock movement may be driven by unstated market expectations.
  • Investor presentation content was unavailable, limiting insight into management's messaging.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-030228
Document: 0001437749-26-030228-index-headers.html0001437749-26-030228
Document: 0001437749-26-030228-index.html0001437749-26-030228
Document: 0001437749-26-030228.txt0001437749-26-030228

Track record

22 reports on NRXP

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Viewing Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026